Ali Sadra

Prof. Ali Sadra


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 January 2022 in Journal of Experimental & Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
Kausik BishayeeKausik Bishayee
Kausik Bishayee
KHKhadija Habib
Khadija Habib
UNUddin Md. Nazim
Uddin Md. Nazim
JKJieun Kang
Jieun Kang
ASAniko Szabo
Aniko Szabo
ASAli Sadra
Ali Sadra
Background: Neuronal-origin HuD (ELAVL4) is an RNA binding protein overexpressed in neuroblastoma (NB) and certain other cancers. The RNA targets of this RNA binding protein in neuroblastoma cells and their role in promoting cancer survival have been unexplored. In the study of modulators of mTORC1 activity under the conditions of optimal cell growth and starvation, the role of HuD and its two substrates were studied. Methods: RNA immunoprecipitation/sequencing (RIP-SEQ) coupled with quantitative real-time PCR were used to identify substrates of HuD in NB cells. Validation of the two RNA targets of HuD was via reverse capture of HuD by synthetic RNA oligoes from cell lysates and binding of RNA to recombinant forms of HuD in the cell and outside of the cell. Further analysis was via RNA transcriptome analysis of HuD silencing in the test cells. Results: In response to stress, HuD was found to dampen mTORC1 activity and allow the cell to upregulate its autophagy levels by suppressing mTORC1 activity. Among mRNA substrates regulated cell-wide by HuD, GRB-10 and ARL6IP1 were found to carry out critical functions for survival of the cells under stress. GRB-10 was involved in blocking mTORC1 activity by disrupting Raptor-mTOR kinase interaction. Reduced mTORC1 activity allowed lifting of autophagy levels in the cells required for increased survival. In addition, ARL6IP1, an apoptotic regulator in the ER membrane, was found to promote cell survival by negative regulation of apoptosis. As a therapeutic target, knockdown of HuD in two xenograft models of NB led to a block in tumor growth, confirming its importance for viability of the tumor cells. Cell-wide RNA messages of these two HuD substrates and HuD and mTORC1 marker of activity significantly correlated in NB patient populations and in mouse xenografts. Conclusions: HuD is seen as a novel means of promoting stress survival in this cancer type by downregulating mTORC1 activity and negatively regulating apoptosis.

26 April 2022 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
Kausik BishayeeKausik Bishayee
Kausik Bishayee
UNUddin Md. Nazim
Uddin Md. Nazim
VKVijay Kumar
Vijay Kumar
JKJieun Kang
Jieun Kang
JKJaebong Kim
Jaebong Kim
ASAli Sadra
Ali Sadra
In MYCN-amplified neuroblastoma (NB), we noticed that the single compound treatment with the HDAC inhibitor vorinostat led to a reprogramming of the glycolytic pathway in these cells. This reprogramming was upregulation of fatty acid oxidation (FAO) and oxidative phosphorylation (OXPHOS), allowing the cells to generate ATP, albeit at a reduced rate. This behavior was dependent on reduced levels of MYCN and a corresponding increase in the levels of PPARD transcription factors. By integrating metabolic and functional studies in NB cells and mouse xenografts, we demonstrate a compensatory upregulation of FAO/OXPHOS metabolism that promotes resistance to HDAC inhibitors. From the additional compounds that could reverse this metabolic reprogramming, the mTORC1 inhibitor sirolimus was selected. Besides both a block of glycolysis and OXPHOS, the HDAC/mTORC1 inhibitor combination produced significantly higher levels of reactive oxygen species (ROS) in the treated cells and in xenograft tumor samples, also a consequence of increased glycolytic block. The lead compounds were also tested for changes in the message levels of the glycolytic enzymes and their pathway activity, and HK2 and GPI glycolytic enzymes were most affected at their RNA message level. This combination was seen with no overall toxicity in treated mice in terms of weight loss or liver/kidney function.

27 June 2022 in Molecules and Cells
Verified
Journal Article
Open access
PDF file
KHKhadija Habib
Khadija Habib
Kausik BishayeeKausik Bishayee
Kausik Bishayee
JKJieun Kang
Jieun Kang
ASAli Sadra
Ali Sadra
HSHuh Sung-Oh
Huh Sung-Oh
Khadija Habib, Kausik Bishayee, Jieun Kang, Ali Sadra*, and Sung-Oh Huh*. Mol. Cells 2022;45:588-602. https://doi.org/10.14348/molcells.2022.0044

2 June 2022 in Cancers
Verified
Journal Article
Open access
PDF file
UNUddin Md. Nazim
Uddin Md. Nazim
Kausik BishayeeKausik Bishayee
Kausik Bishayee
JKJieun Kang
Jieun Kang
DYDongkwan Yoo
Dongkwan Yoo
HSHuh Sung-Oh
Huh Sung-Oh
ASAli Sadra
Ali Sadra
Studies in targeting metabolism in cancer cells have shown the flexibility of cells in reprogramming their pathways away from a given metabolic block. Such behavior prompts a combination drug approach in targeting cancer metabolism, as a single compound may not address the tumor intractability. Overall, mammalian target of rapamycin complex 1 (mTORC1) signaling has been implicated as enabling metabolic escape in the case of a glycolysis block. From a library of compounds, the tyrosine kinase inhibitor ponatinib was screened to provide optimal reduction in metabolic activity in the production of adenosine triphosphate (ATP), pyruvate, and lactate for multiple myeloma cells; however, these cells displayed increasing levels of oxidative phosphorylation (OXPHOS), enabling them to continue generating ATP, although at a slower pace. The combination of ponatinib with the mTORC1 inhibitor, sirolimus, blocked OXPHOS; an effect also manifested in activity reductions for hexokinase 2 (HK2) and glucose-6-phosphate isomerase (GPI) glycolysis enzymes. There were also remarkably higher levels of reactive oxygen species (ROS) produced in mouse xenografts, on par with increased glycolytic block. The combination of ponatinib and sirolimus resulted in synergistic inhibition of tumor xenografts with no overt toxicity in treated mice for kidney and liver function or maintaining weight.

4 May 2018 in Animal Cells and Systems
Verified
Journal Article
Open access
JCJaeyoung Cho
Jaeyoung Cho
HKHyuck-Se Kweon
Hyuck-Se Kweon
HSHuh Sung-Oh
Huh Sung-Oh
ASAli Sadra
Ali Sadra
The primary aim of this study was to determine whether the oral administration of AD-lico™, a functional extract from Glycyrrhiza inflata in combination with 5-aminosalicylic acid (5-ASA) could ameliorate the inflammatory symptoms in dextran sulfate sodium (DSS)-induced colitis in rodents. This DSS rodent model is used to study drug candidates for colitis, as part of the spectrum of diseases falling under the inflammatory bowel disease (IBD) category. Here, with oral AD-lico™ administration, there was a substantial disruption of the colonic architectural changes due to DSS and a significant reduction in colonic myeloperoxidase (MPO) activity, a marker of colitis. In the same samples, there were also reduced levels of colonic and serum IL-6 in the oral AD-lico™ treated rats. This study also addressed the possible mechanisms for AD-lico™ mediated changes on colonic inflammation markers. These included the observations that AD-lico™ dampened the IL-6 proinflammatory-signaling pathway in THP-1 human monocytic cells and reduced the TNFα-mediated upregulation of surface adhesion molecule ICAM-1 in human umbilical vein endothelial cells (HUVECs). Finally, it was shown that AD-lico™ could be combined with 5-ASA in reducing the inflammatory markers for colorectal sites affected by colitis, a first study of its kind for a combination therapy.

8 February 2022 in Journal of Experimental & Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
Kausik BishayeeKausik Bishayee
Kausik Bishayee
KHKhadija Habib
Khadija Habib
UNUddin Md. Nazim
Uddin Md. Nazim
JKJieun Kang
Jieun Kang
ASAniko Szabo
Aniko Szabo
ASAli Sadra
Ali Sadra